Cue Biopharma Inc (CUE) Stock Price, Quote & News

Latest News on CUE

Nov 29, 2024, 4:30 PM EST - 7 weeks ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 2 months ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 2 months ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 2 months ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 8, 2024, 1:30 PM EST - 2 months ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 3 months ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 4 months ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 4 months ago

Cue Biopharma Announces Proposed Public Offering

Sep 9, 2024, 8:00 AM EDT - 4 months ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 19, 2024, 8:17 PM EDT - 5 months ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 4:05 PM EDT - 5 months ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 8:00 AM EDT - 9 months ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 24, 2024, 10:01 AM EDT - 9 months ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 9:43 PM EDT - 10 months ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 4:05 PM EDT - 10 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Feb 29, 2024, 10:00 AM EST - 11 months ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Nov 22, 2023, 8:00 AM EST - 1 year ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 11, 2023, 3:32 PM EST - 1 year ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 8:00 AM EST - 1 year ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Aug 9, 2023, 10:23 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:10 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 7, 2023, 8:00 AM EDT - 1 year ago

Cue Biopharma to Host Investor Call

Jun 5, 2023, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 1 year ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2023, 4:35 PM EDT - 1 year ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 8, 2023, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

Apr 12, 2023, 8:00 AM EDT - 1 year ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Mar 21, 2023, 11:00 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 4:10 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 1, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

Feb 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

Feb 16, 2023, 10:30 AM EST - 2 years ago

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Feb 16, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

Feb 1, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two February 2023 Scientific Conferences

Jan 23, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Announces Chief Medical Officer Transition

Nov 14, 2022, 11:23 PM EST - 2 years ago

Cue Biopharma, Inc. (CUE) Q3 2022 Earnings Call Transcript

Nov 14, 2022, 4:01 PM EST - 2 years ago

Cue Biopharma Reports Third Quarter 2022 Financial Results

Nov 14, 2022, 8:20 AM EST - 2 years ago

Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing

Nov 9, 2022, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

Nov 7, 2022, 8:00 AM EST - 2 years ago

Cue Biopharma to Host Business Update Call and Webcast

Aug 23, 2022, 8:13 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2022 Results - Earnings Call Transcript

Aug 4, 2022, 4:30 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2022 Financial Results

Jul 11, 2022, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

Jun 1, 2022, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Jefferies Healthcare Conference

May 26, 2022, 5:00 PM EDT - 2 years ago

Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 11, 2022, 10:25 AM EDT - 2 years ago

Market Cap	82.99M
Revenue (ttm)	5.49M
Net Income (ttm)	-50.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-924.04%
Debt to Equity Ratio	0.21

Volume	201,600
Avg Vol	478,176
Day's Range	N/A - N/A
Shares Out	63.35M
Stochastic %K	20%
Beta	1.63
Analysts	Strong Sell
Price Target	$3.60